WAYNE, Pa., Feb. 2, 2015 /CNW/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a specialty pharmaceutical company focused on developing and commercializing effective pain medications while delivering peace of mind to physicians and patients, today announced that Bob Radie, president and chief executive officer, will present at upcoming conferences:
Virtual Investor Conferences
Date and Time: Thursday, February 5, 2015 at 1:00 PM EST
17th Annual BIO CEO & Investor Conference
Date and Time: Monday, February 9 at 5:30 PM EST
Egalet, a fully integrated commercial specialty pharmaceutical company, is focused on developing, manufacturing and marketing innovative pain treatments. The Company has two approved products: OXAYDO (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting, for the management of acute and chronic moderate to severe pain where an opioid is appropriate, and SPRIX® (ketorolac tromethamine) Nasal Spray, a non-steroidal anti-inflammatory drug (NSAID), indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level. In addition, using Egalet's proprietary Guardian™ Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full prescribing information for OXAYDO and SPRIX and additional information on Egalet can be found at www.egalet.com.
SOURCE Egalet Corporation
For further information: Investor and Media: E. Blair Clark-Schoeb, Senior Vice President, Communications, Email: firstname.lastname@example.org, Tel: 917-432-9275, http://www.egalet.com